

THERAVANCE INC  
Form 8-K  
January 15, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**Current Report Pursuant**  
**to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): **January 15, 2008**

---

**THERAVANCE, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**

(State or Other Jurisdiction  
of Incorporation)

**000-30319**

(Commission File Number)

**94-3265960**

(I.R.S. Employer  
Identification Number)

**901 Gateway Boulevard**  
South San Francisco, California 94080

Edgar Filing: THERAVANCE INC - Form 8-K

(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On January 3, 2008 Theravance, Inc. and GlaxoSmithKline Plc issued a joint press release with information regarding a recently-completed Phase 2 study of the lead inhaled corticosteroid (ICS) GW685698 ( 698) asset in the Horizon program to develop a next-generation combination product involving an ICS and a long-acting beta agonist. In the Phase 2 study, 698 demonstrated once-a-day efficacy in patients with moderate asthma, with improvements in lung function in excess of 200mL. Further information regarding the results of this Phase 2 study of 698 are summarized in the slide on Exhibit 99.1 to this report and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Slide Regarding 698 ICS Phase 2 QD Dose-Ranging Study

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THERAVANCE, INC.**

Date: January 15, 2008

By: **/s/ Rick E Winningham**  
**Rick E Winningham**  
**Chief Executive Officer**

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Slide Regarding 698 ICS Phase 2 QD Dose-Ranging Study